Six-year disease-free survival of a patient with metastatic eyelid squamous cell carcinoma and colon adenocarcinoma after repeated postoperative adoptive immunotherapy.
A 74-year-old male was affected concurrently with squamous cell carcinoma of the left eyelid and adenocarcinoma of the colon, both with lymph node metastasis. He underwent exenteration of the left orbit with left modified radical neck dissection and subsequently resection of the transverse colon with regional lymph node dissection. The patient has been treated by an adoptive immunotherapy as a sole postoperative modality without receiving any chemotherapeutic agents causing immunosuppression. For the adoptive immunotherapy, autologous peripheral blood lymphocytes were activated with an immobilized anti-CD3 antibody and IL-2 for 14 days (the CD3-AT cells). The infusion with 1.38 x 10(10) CD3-AT cells has been repeated 150 times in total at the time of writing. Neither recurrence nor additional metastasis has been detected for 6 years after surgery.
Kawamura
A
A
Department of Immunology, Institute of Medical Science, The University of Tokyo, Japan.
Sekine
T
T
Sekiguchi
M
M
Yanoma
S
S
Kaneko
A
A
Haneda
T
T
Moriya
Y
Y
Hayasaka
K
K
Kakizoe
T
T
D000230:Adenocarcinoma / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D018572:Disease-Free Survival; D005142:Eyelid Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008213:Lymphocyte Activation; D008297:Male; D016853:Muromonab-CD3 / Q000276:immunology; D037981:Neck Dissection; D009378:Neoplasms, Multiple Primary; D011182:Postoperative Care
D016853:Muromonab-CD3